Roche: Encouraging updated data for risdiplam in SMA (
Roche: (NEUTRAL, Fair Value CHF274 vs. CHF266 (+13%))Encouraging updated data for risdiplam in SMA
Roche yesterday presented updated clinical data for its oral investigational drug for SMA risdiplam which remain very encouraging. When comparing the data to AVXS-101 in SMA type 1 and 2, we still believe that Novartis stands out with the most promising agent but we see it taking mainly the incidence market in the infancy while risdiplam is tailored to address the prevalence adult population in all SMA subtypes and maybe also non responders in second-line or as add-on. We derive a USD3bn peak sales from this opportunity. We take a 60% PoS, hence our increase in the FV. Separately, Roche publishes average data for baloxavir marboxil vs Tamiflu in high-risk patients with influenza.
Click here to download
Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.